Phymatrics (PHMX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Phymatrics (PHMX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew Q. Viet who wrote (95)	11/28/1997 9:55:00 AM
From: Ross	of 118

WEST PALM BEACH, Fla., Nov 26 (Reuters) - PhyMatrix Corp said Wednesday it signed an agreement with Organogenesis Inc to assess Apligraf (Graftskin) in the treatment of pressure sores. Apligraf is manufactured, living human skin equivalent developed by Organogenesis for the treatment of wounds. PhyMatrix, through its wholly owned subsidiary, Clinical Studies Ltd, will assess the efficacy and safety of Apligraf in the treatment of pressure sores. The study also will assess the economic benefits of Apligraf in the treatment of these wounds. More than two million patients in the United States are estimated to suffer from pressure sores. REUTERSRtr 18:26 11-26-97

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next